Dementia Drug Candidate Advances Toward Lewy Trial
Adults with dementia with Lewy bodies may eventually gain a treatment option if the zervimesine trial program succeeds.
Updated on Nov. 5, 2026 in Alzheimer’s
Cognition Therapeutics reported its third-quarter 2026 financial results on November 5, 2026, showing about $31.5 million in cash and restricted cash equivalents as of September 30. The company also said it completed a trial protocol for a planned registrational study of zervimesine in dementia with Lewy bodies, a condition affecting an estimated 1.4 million Americans.
Why it matters
Dementia with Lewy bodies has no approved disease-modifying treatments, so progress on a planned registrational study matters to patients and families tracking the Alzheimer's and dementia pipeline. The company's update shows how early-stage candidates are moving toward regulatory review, though the drug's benefit remains unproven.
The figures come from the company's own quarterly financial report rather than an independent clinical study. Efficacy data for zervimesine in dementia with Lewy bodies are still pending the Phase 2 START results.
The players
Cognition Therapeutics
A Purchase, New York-based biotechnology company developing treatments for Alzheimer's disease and related dementias, including zervimesine.
U.S. Food and Drug Administration
The federal agency that reviews and approves drugs and oversees clinical trial design, including the Office of Neuroscience that worked with Cognition on the protocol.
National Institute on Aging
A component of the National Institutes of Health that funds Alzheimer's and aging research and is supporting Cognition's grant work.
The details
Zervimesine is an investigational oral compound that Cognition Therapeutics is developing for Alzheimer's disease and related dementias. During 2026 the company worked with the Office of Neuroscience at the FDA to build the protocol for a registrational trial in dementia with Lewy bodies, a disease marked by fluctuating cognition, visual hallucinations and movement problems. Research spending rose as trial activity increased with contract research organizations, while general and administrative costs fell on lower professional fees.
Timeline
2026: FDA collaboration produces the registrational trial protocol for zervimesine.
September 30, 2026: Third-quarter financial period ends with reported cash on hand.
November 5, 2026: Financial results and business update are released.
Second half of 2027: Top-line results from the Phase 2 START study are expected.
Health Landscape
Dementia with Lewy bodies has lacked an approved disease-modifying therapy, leaving clinicians to manage symptoms. Progress from early trials to registrational study design marks a step in a field where most candidates have not reached approval.
If you or a family member have been diagnosed with dementia with Lewy bodies, this development is a reminder that clinical trials are an option worth discussing with a neurologist. Patients experiencing cognitive fluctuations, visual hallucinations or movement changes should continue routine specialist care while the research unfolds.
The takeaway
Dementia with Lewy bodies is a common cause of cognitive decline with few approved treatments, so tracking trial progress is useful for patients and caregivers. Ask a neurologist whether clinical trials for Lewy body dementia may be appropriate to discuss.
What happens next
Top-line results from the Phase 2 START study are expected in the second half of 2027, which will show whether the candidate advances toward the planned registrational trial.
Further reading
For broader context on the research pipeline, see Alzheimer's coverage in New York.
